Moderna picks up a $75M cash windfall as longtime collaborator Vertex signs up for a gene editing assault on cystic fibrosis
After nailing down the top drug franchise in cystic fibrosis, Vertex $VRTX is turning to the mRNA aficionados at Moderna $MRNA to use gene editing tech for a generation 2.0 attempt to master the disease. This is their 3rd pact together in 4 years as they jointly set their sights on the patients who are toughest to treat.
Researchers at Moderna and Vertex will now work together to develop lipid nanoparticles and mRNA to deliver gene editing tools to cells in the lung to spur production of functional cystic fibrosis transmembrane conductance regulator (CFTR) protein.
Unlock this article instantly by becoming a free subscriber.
You’ll get access to free articles each month, plus you can customize what newsletters get delivered to your inbox each week, including breaking news.